Basic | |
---|---|
Market Cap | $37.1M |
Price | $9.5 |
52 Week Range | 4.56-19 |
Beta | 0.05 |
Margins | |
Gross Profit Margin | 116.10% |
Operating Profit Margin | 0.12% |
Net Profit Margin | 0.12% |
Valuation (TTM) | |
P/E Ratio | -27.25 |
Price to Sales Ratio | -0.00 |
Price to Book Ratio | -21.39 |
PEG Ratio | -1.49 |
Biotechnology
Healthcare
31
2021-10-15T00:00:00.000Z
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
212 994 8250
149 Fifth Avenue, New York, NY, 10010, US
0001840229